Metraipolis › archive › dc_eb5c262820ee

Preclinical Safety Profile of Deg-AZM, a Clinical-Stage New Transgelin Agonist: hERG Inhibition Study In Vitro, Cardiovascular-Respiratory Pharmacology, and… — Europe PMC PMID:41007743

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41007743
DOI
10.3390/biomedicines13092180
License (as archived)
solo-consultazione
Archived
2026-11-10T02:29:19.551Z
SHA-256 of the archived text
36904bd704d591b3943938591319b5be97a10e5c167a84e879ccb3860e29e502
Stable URL of this page
https://metraipolis.com/documento/dc_eb5c262820ee

How to cite

Preclinical Safety Profile of Deg-AZM, a Clinical-Stage New Transgelin Agonist: hERG Inhibition Study In Vitro, Cardiovascular-Respiratory Pharmacology, and… — Europe PMC PMID:41007743 — Europe PMC (en), https://europepmc.org/article/MED/41007743 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_eb5c262820ee (Metraipolis archive dc_eb5c262820ee, sha256 36904bd704d591b3943938591319b5be97a10e5c167a84e879ccb3860e29e502)
BibTeX
@misc{dceb5c262820ee,
  title = {Preclinical Safety Profile of Deg-AZM, a Clinical-Stage New Transgelin Agonist: hERG Inhibition Study In Vitro, Cardiovascular-Respiratory Pharmacology, and… — Europe PMC PMID:41007743},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41007743},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_eb5c262820ee; sha256 36904bd704d591b3943938591319b5be97a10e5c167a84e879ccb3860e29e502},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41007743. Agents can read the archived copy with the MCP tool read_document.